[Market Focus] Lapas Hits Upper Price Limit on Microneedle Breakthroughs from Obesity to Skin Aging

Lapas hit the upper price limit.

At 9:07 a.m. on May 26, Lapas surged by 29.75% (up 4,850 won) from the previous trading day, reaching the upper price limit of 21,150 won.

Earlier, on May 19, Lapas, a company specializing in microneedles, attracted market attention by announcing the launch of a new product, "Reti-RN" patch, which is the world's first to stably combine retinol and polydeoxyribonucleotide (PDRN) ingredients.

Reti-RN is a skincare product that combines retinol, known for its effectiveness in preventing skin aging, with PDRN, extracted from salmon DNA and recognized for its outstanding skin regeneration and elasticity improvement effects. It is being evaluated as significant because Lapas has succeeded in combining retinol and PDRN?two ingredients previously difficult to stably blend in a single formulation?using its proprietary technology.

Additionally, Lapas is expected to be active in the patch-type obesity drug market. Last month, Lapas announced the results of a Phase 1 clinical trial showing that the bioavailability of semaglutide (ingredient name of Wegovy) using microneedle technology was approximately 30% higher than that of the existing subcutaneous injection (SC) formulation. Considering that the bioavailability of Novo Nordisk's currently marketed oral semaglutide "Rybelsus" is less than 0.5% compared to the SC formulation, the absorption efficiency is about 60 times higher.

This content was produced with the assistance of AI translation services.